Ravulizumab

Definition

A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing. C5, a complement pathway protein, is expressed at high levels by the liver.

Also known as ALXN 1210, ALXN-1210, ALXN1210, RAVULIZUMAB, Ravulizumab-cwvz, Ultomiris — per NCIT

Also identified as

• ATC L04AJ02 per RXNORM
• NCIT NCIT:C124657 per NCIT
• SCTID 783439006 per RXNORM
• SCTID 783573003 per RXNORM
• UNII C3VX249T6L per RXNORM

Indications